Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 8, 2011, Pages 1146-1153

  Stiff, Patrick J ^a   Micallef, Ivana ^b   Nademanee, Auayporn P ^c   Stadtmauer, Edward A ^d   Maziarz, Richard T ^e   Bolwell, Brian J ^f   Bridger, Gary ^g   Marulkar, Sachin ^g   Hsu, Frank J ^g   DiPersio, John F ^h  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b MAYO CLINIC   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g GENZYME CORPORATION   (United States)

^h WASHINGTON UNIVERSITY   (United States)

Author keywords

Autologous peripheral blood stem cell transplantation; Cell dose; Platelet recovery; Plerixafor

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLERIXAFOR;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CD34 SELECTION; CONTROLLED STUDY; CONVALESCENCE; CORRELATIONAL STUDY; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MORNING DOSAGE; MULTIPLE MYELOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ANTIGENS, CD34; BLOOD PLATELETS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLATELET COUNT; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 79960216473     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.11.021     Document Type: Article

References (32)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91-97.
2. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005, 23:9227-9233.
4. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
5. Shipp M.A., Abeloff M.D., Antman K.H., et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999, 17:423-429.
6. Akhtar S., Weshi A.E., Rahal M., et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008, 49:769-778.
7. Demirer T., Buckner C.D., Gooley T., et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996, 17:937-941.
8. Desikan K.R., Barlogie B., Jagannath S., et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998, 16:1547-1553.
9. Kuittinen T., Nousiainen T., Halonen P., Mahlamaki E., Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:907-912.
10. Perea G., Sureda A., Martino R., et al. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001, 80:592-597.
11. Pusic I., Jiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
12. Giralt S., Stadtmauer E.A., Harousseau J.L., et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009, [Epub ahead of print].
13. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
14. Duggan P.R., Guo D., Luider J., et al. Predictive factors for long-term engraftment of autologous blood stem cells. Bone Marrow Transplant 2000, 26:1299-1304.
15. Siena S., Schiavo R., Pedrazzoli P., Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000, 18:1360-1377.
16. Sola C., Maroto P., Salazar R., et al. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999, 4:195-209.
17. Kiss J.E., Rybka W.B., Winkelstein A., et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997, 19:303-310.
18. Schwella N., Beyer J., Schwaner I., et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 1996, 14:1114-1121.
19. Blystad A.K., Delabie J., Kvaloy S., et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004, 125:605-612.
20. Toor A.A., Ayers J., Strupeck J., et al. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol 2004, 124:769-776.
21. Limat S., Woronoff-Lemsi M.C., Milpied N., et al. Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. Eur J Cancer 2000, 36:2360-2367.
22. Schulman K.A., Birch R., Zhen B., Pania N., Weaver C.H. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999, 17:1227.
23. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
24. Hatse S., Princen K., Bridger G., De Clercq E., Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527:255-262.
25. Rosenkilde M.M., Gerlach L.O., Hatse S., et al. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 2007, 282:27354-27365.
26. Devine S.M., Flomenberg N., Vesole D.H., et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004, 22:1095-1102.
27. Liles W.C., Broxmeyer H.E., Rodger E., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
28. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
29. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
30. Micallef I.N., Stiff P.J., DiPersio J.F., et al. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009, 15:1578-1586.
31. Ninan M.J., Flowers C.R., Roback J.D., Arellano M.L., Waller E.K. Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2007, 13:895-904.
32. Micallef I.N., Stiff P., Stadtmauer E., et al. Similar 1 year survival of patients receiving plerixafor (Mozobil®) plus G-CSF versus placebo plus G-CSF mobilized autologous grafts: results from 2 phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front-line or rescue mobilization. Blood 2009, Abstract 2319.